Use of cannabinoids in the treatment of epilepsy

Abstract

The present invention relates in the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Surge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

1 - 19 . (canceled) 
     
     
         20 . A method of treating Sturge Weber syndrome in a subject, comprising administering to the subject a therapeutically effective amount of cannabidiol (CBD), wherein the CBD is a highly purified extract of  cannabis  which comprises at least 98% (w/w) CBD. 
     
     
         21 . The method of  claim 20 , wherein the treating comprises treating seizures in a subject having Sturge Weber syndrome. 
     
     
         22 . The method of  claim 20 , wherein the treating comprises treating non-seizure symptoms in a subject having Sturge Weber syndrome. 
     
     
         23 . The method of  22 , wherein the non-seizure symptoms are one or more of mood, behavior, cognitive function and general quality of life. 
     
     
         24 . The method of  claim 20 , wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AEDS). 
     
     
         25 . The method of  claim 20 , wherein the extract comprises less than 0.15% tetrahydrocannabinol (THC). 
     
     
         26 . The method of  claim 20 , wherein the extract further comprises up to 1% cannabidivarin (CBDV). 
     
     
         27 . The method of  claim 20 , wherein the extract further comprises between 0.1 and 1.0% CBDV. 
     
     
         28 . The method of  claim 20 , wherein the CBD is present as a synthetic compound. 
     
     
         29 . The method of  claim 25 , wherein the one or more AED is selected from the group consisting of: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide. 
     
     
         30 . The method of  claim 25 , wherein a number of different AEDs that are used in combination with the CBD is reduced relative to the number of AEDs administered prior to treatment with CBD. 
     
     
         31 . The method of  claim 25 , wherein the dose of anti-epileptic drugs that are used in combination with the CBD is reduced relative to the dose of AEDs administered prior to treatment with CBD. 
     
     
         32 . The method of  claim 20 , wherein the dose of CBD is greater than 5 mg/kg/day. 
     
     
         33 . The method of  claim 20 , wherein the subject is a child or young adult. 
     
     
         34 . The method of  claim 20 , wherein the dose of CBD ranges from about 5 mg/kg/day to about 25 mg/kg/day. 
     
     
         35 . The method of  claim 20 , wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments, up to 25 mg/kg/day.